Predicted protein targets (top 2)
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL22338578 | 0.98 | ARG2 (0.88) | ARG2ARG1 | |
| SCHEMBL21285674 | 0.95 | ARG2 (1.00) | ARG2ARG1 | |
| SCHEMBL893861 | 0.95 | ARG2 (1.00) | ARG2ARG1 | |
| Hydrochloric Acid SCHEMBL894870 | 0.94 | ARG2 (0.97) | ARG2ARG1 | |
| SCHEMBL30169846 | 0.81 | ARG1 (0.60) | ARG2ARG1 | |
| SCHEMBL7094527 | 0.81 | ARG2 (0.60) | ARG2ARG1 | |
| SCHEMBL31042229 | 0.79 | ARG1 (0.59) | ARG2ARG1 | |
| SCHEMBL31042202 | 0.79 | ARG1 (0.59) | ARG2ARG1 | |
| SCHEMBL31042217 | 0.79 | ARG1 (0.59) | ARG2ARG1 | |
| SCHEMBL31042199 | 0.79 | ARG1 (0.59) | ARG2ARG1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12502398-B2 | Combination therapy for treating cancer | ASTRAZENECA AB (SE) | 2025-12-23 | — | — | US | disclosed |
| CN-119868377-A | Combination therapy for the treatment of cancer | 阿斯利康(瑞典)有限公司 | 2025-04-25 | — | — | CN | disclosed |
| CN-111770756-B | Non-natural amino acid derivative, pharmaceutical composition containing same, and preparation method and application thereof | 四川科伦博泰生物医药股份有限公司 | 2023-03-31 | — | — | CN | disclosed |
| US-20220409642-A1 | COMBINATION THERAPY FOR TREATING CANCER | ASTRAZENECA AB (SE) | 2022-12-29 | — | — | US | disclosed |
| EP-4054591-A1 | COMBINATION THERAPY FOR TREATING CANCER | Astrazeneca AB (SE) | 2022-09-14 | — | — | EP | disclosed |
| CN-114599372-A | Combination therapy for the treatment of cancer | 阿斯利康(瑞典)有限公司 | 2022-06-07 | — | — | CN | disclosed |
| CN-111770756-A | Non-natural amino acid derivative, pharmaceutical composition containing same, and preparation method and application thereof | 四川科伦博泰生物医药股份有限公司 | 2020-10-13 | — | — | CN | disclosed |
| WO-2020161675-A1 | ARGINASE INHIBITORS AND METHODS OF USE THEREOF | ASTRAZENECA AB (SE) | 2020-08-13 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20220409642-A1 | COMBINATION THERAPY FOR TREATING CANCER | IL2, IFNG, PBK | ARG2 172/4885ARG1 143/4885 |
| US-12502398-B2 | Combination therapy for treating cancer | IL2, IFNG, PBK | ARG2 172/4885ARG1 143/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.